Professor of the school of future technology of Peking University and once served as an assistant professor of Massachusetts General Hospital of Harvard Medical School

Professor Xiong Jingwei has published the first high-level paper on CRISPR gene editing technology in China. He is a top expert in the field of organ regenerative medicine. The International Society for Regenerative Biology Webinar academic exchange, initiated and organized the National Organ Regeneration Academic Annual Conference, the main achievements include:

  • The first to use CRISPR technology to establish zebrafish and rat genetic mutants in the world;
  • Take the lead in establishing a high-throughput chemical small molecule zebrafish screening platform and a cardiomyocyte proliferation-promoting platform in China, and discover a variety of small molecule candidate drugs that promote myocardial regeneration or inhibit cerebral hemorrhage;
  • The first to discover a combination of chemical small molecules to treat myocardial infarction in adult rats and mice.

Professor Xiong Jingwei

Has undertaken the National Natural Science Foundation of China
973. 12 national-level subjects including national key R&D plans

So far, he has published more than 60 papers, and has undertaken 12 national-level projects such as the National Natural Science Foundation of China, 973, and the National Key R&D Program, and has cooperated with large international pharmaceutical companies such as AstraZeneca and Bayer. Fund projects. He has been successively rated as a foreign expert by the State Administration of Foreign Experts Affairs, a research team leader of the State Key Laboratory of Natural Medicines and Biomimetic Drugs at Peking University, a member of the overall expert group of the Ministry of Science and Technology's "Developmental Programming and Metabolic Regulation Project", and awarded the National Institutes of Health K01 Young Scholar Award, Harvard University Milton Award, Peking University Shuren Award, Bayer Medical Research Award, Nanjing Science and Technology Top Program, and Jiangsu Provincial Innovation and Entrepreneurship Program.

Warm and Moist , make concerted efforts

Nanjing RainGene Biotechnology Co., Ltd. has a founder team with professional complementarity, strong innovation ability and strong combat effectiveness. They are domestic top talents in molecular biology and have a high level of domestic scientific research and technology. Since its establishment, the company has always regarded technology research and development and talent training as the development goal of the company. The company has set up a special technology R & D department. Relying on the technical support of the Molecular Research Institute of Peking University, 20% of the doctoral and master's personnel come from the Molecular Research Institute of Peking University, and 80% of the undergraduate personnel come from excellent colleges and universities.

Copyright © 2022 Nanjing RainGene Biotechnology Co., Ltd. All Rights Reserved 苏ICP备2022008727号